Related Experiment Videos

Pentoxyfylline in and prevention and treatment of chronic lung disease

R Lauterbach1, D Pawlik, M Zembala

  • 1Department of Neonatology, Medical College Jagiellonian University, Cracow, Poland. lauterbach@pro.onet.pl

Acta Paediatrica (Oslo, Norway : 1992). Supplement
|March 24, 2004
PubMed

Insights

Pentoxifylline demonstrates anti-inflammatory benefits, reducing mortality in sepsis and bone marrow transplant patients. It may also help treat Bronchopulmonary Dysplasia (BPD) in infants.

Area of Science:

  • Pharmacology
  • Neonatology
  • Critical Care Medicine

Background:

  • Pentoxifylline exhibits anti-inflammatory properties with documented clinical benefits.
  • These benefits include reduced mortality in bone marrow transplant recipients and peritonitis patients.
  • Pentoxifylline administration is also linked to decreased mortality in infants with sepsis.

Purpose of the Study:

  • To explore the potential role of pentoxifylline in Bronchopulmonary Dysplasia (BPD).
  • To evaluate pentoxifylline's efficacy based on its anti-inflammatory, bronchodilator, diuretic, and respiratory stimulant effects.

Main Methods:

  • Interim analysis of a prophylactic trial investigating pentoxifylline's use.
  • Comparison of pentoxifylline and dexamethasone efficacy in established BPD.

Main Results:

  • Preliminary findings suggest pentoxifylline may decrease treatment needs post-neonatal period.
  • In established BPD cases, pentoxifylline showed comparable efficacy to dexamethasone.

Conclusions:

  • Pentoxifylline's multifaceted effects suggest a potential therapeutic role in BPD.
  • Further research into pentoxifylline for BPD management is warranted based on preliminary data.

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...